Search
CSPC Nuokang: Type 1 Therapeutic Biological Product SYS6041 Secures Approval for Clinical Drug Trials
15 hour ago /
Read about 0 minute
Author：小编
CSPC Nuokang (300765) has officially declared that its majority-owned subsidiary, CSPC Juyan Biopharmaceuticals Co., Ltd., has recently been granted the 'Approval Notice for Clinical Drug Trials' by the National Medical Products Administration for SYS6041 (a Folate Receptor-targeted Antibody-Drug Conjugate, or ADC). This approval paves the way for the clinical investigation of SYS6041 as part of a combination therapy regimen aimed at treating ovarian cancer.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
